European Pharmaceutical Review

FEBRUARY 28, 2023

The largest cell therapy trial to date for chronic heart failure due to low ejection fraction (EF), has shown that mesenchymal precursor cells (MPCs) have potential for the first time to address inflammation. For the first time, we’ve discovered that stem cells can successfully treat the inflammation that causes heart failure.”

Medical 95

Medical Patients Leads Pharmaceutical 95

Pharmacy Times

OCTOBER 27, 2023

Sotagliflozin (Inpefa) is an orally administered dual SGLT1/2 inhibitor that reduces the risk of death due to heart failure.

26

26

European Pharmaceutical Review

FEBRUARY 7, 2023

Forxiga (dapagliflozin) has been approved in the European Union for heart failure (HF) with reduced ejection fraction (HFrEF) across the full spectrum of left ventricular ejection fraction (LVEF). AstraZeneca’s Forxiga is the first and only heart failure therapy with proven mortality benefit across the full ejection fraction range.

Patients 85

Patients Medicine Pharmaceutical 85

European Pharmaceutical Review

DECEMBER 12, 2022

The Medicines and Healthcare products Regulatory Agency ( MHRA ) has granted a licence extension for FORXIGA (dapagliflozin) in Great Britain for symptomatic chronic heart failure (HF) across the full spectrum of left ventricular ejection fraction (LVEF). Clinical trial data assessing dapagliflozin for chronic heart failure.

Transportation 103

Transportation Medical science Safety Patients 103

Pharmaceutical Technology

DECEMBER 20, 2023

Rexlemestrocel-L is under clinical development by Mesoblast and currently in Phase III for Congestive Heart Failure (Heart Failure).

40

40

Pharmaceutical Technology

DECEMBER 20, 2023

MYK-224 is under clinical development by Bristol-Myers Squibb and currently in Phase II for Diastolic Heart Failure (HFpEF).

52

52

Pharmaceutical Technology

APRIL 14, 2023

ISX9-CPC is IPS HEART’s first patented drug candidate, and uses small molecule ISX-9 to reprogramme the iPSCs into new functional human heart muscle to treat heart failure and Duchenne cardiomyopathy. ISX9-CPC is expected to become the company’s first drug to be used clinically in humans.

Food and Drug Administration 98

Food and Drug Administration FDA Food Patients 98

Pharmaceutical Technology

DECEMBER 20, 2023

Ferric carboxymaltose is under clinical development by Vifor Pharma Management and currently in Phase III for Congestive Heart Failure (Heart…

Management 40

Management Pharma 40

Pharmaceutical Technology

SEPTEMBER 9, 2022

US-based biotech company Gatehouse Bio is extending its collaboration with AstraZeneca for developing RNA therapeutics to treat heart failure with preserved ejection fraction (HFpEF). The mutations were expected to regulate biological pathways that are related to a clinical syndrome.

Pharmaceutical 98

Pharmaceutical Patients 98

Legacy MEDSearch

MARCH 24, 2023

Ancora Heart, Inc., a company developing a completely transcatheter device-based therapy to address heart failure (HF), announced that patients treated with the investigational AccuCinch ® Ventricular Restoration System demonstrated improvement in HF patient outcomes and beneficial changes in the structure of the heart.

Patients 52

Patients Recruitment Medical Medicine 52

Pharmaceutical Technology

SEPTEMBER 1, 2023

Bayer adds three new Phase III heart failure studies to the Kidney and type 2 diabetes drug, Kerendia, clinical development programme.

52

52

Medgadget

JULY 29, 2022

Bodyport , a medtech company based in San Francisco, developed the Bodyport Cardiac Scale, a set of weighing scales that can non-invasively assess fluid status and heart function. Cardiac monitoring is especially helpful in those living with advanced heart disease, such as heart failure.

Patients 81

Patients Networking Healthcare Healthcare 81

Pharmacy Times

JANUARY 5, 2024

Conclusions could not be made regarding whether lower risk was associated with improvement in heart failure or if the success of optimal medications led to better clinical outcomes.

Leads 48

Leads Medical 48

Pharmaceutical Technology

MAY 10, 2023

The US Food and Drug Administration (FDA) has granted approval for AstraZeneca ’s Farxiga (dapagliflozin) to reduce the risks of cardiovascular (CV) death, hospitalisation for heart failure (hHF) and urgent heart failure (HF) emergency care visits in HF adult patients.

Food and Drug Administration 52

Food and Drug Administration FDA Food Patients 52

PharmExec

JANUARY 2, 2024

Pharma leaders are increasingly allocating budget toward real-time clinical alerts that integrate with and improve patient care.

Pharma 52

Pharma Patients Manufacturing 52

Legacy MEDSearch

AUGUST 10, 2023

It is designed to be used alongside standard-of-care assessment in a hospital or clinical setting to identify hemodynamic congestion and support personalized treatment of HF. to conduct a larger 1200-patient study to ensure the device is generalizable across a global heart failure population. “Andrew J. “Andrew J.

Food and Drug Administration 52

Food and Drug Administration Management Recruitment Medical 52

Legacy MEDSearch

FEBRUARY 24, 2023

Eko , a digital health company applying artificial intelligence (AI) in the fight against heart and lung disease, today announced the launch of the SENSORA Cardiac Disease Detection Platform. Left undetected and untreated, it can lead to heart failure, stroke, blood clots, and death.

Physicians 98

Physicians Recruitment Patients FDA 98

pharmaphorum

AUGUST 30, 2022

AstraZeneca’s Farxiga reduced the risk of hospitalisation and death in people with all types of heart failure in the DELIVER trial, which could dramatically increase the population of patients eligible for treatment with the SGLT2 inhibitor. Now, AZ has an opportunity to redress the balance. .”

Medical science 59

Medical science Patients Marketing Sales 59

Legacy MEDSearch

NOVEMBER 2, 2022

per share in cash if certain commercial and clinical milestones are achieved. The transaction broadens Johnson & Johnson MedTech’s (JJMT) position as a growing cardiovascular innovator, advancing the standard of care in one of healthcare’s largest unmet need disease states: heart failure and recovery.

Recruitment 98

Recruitment Medical Leads Patients 98

pharmaphorum

AUGUST 2, 2022

Heart failure. Heart failure is one of the main causes of disability and mortality from cardiovascular pathology, its incidence is steadily increasing. Therefore, dehydration therapy is an important component of the treatment of patients with heart disease. Lasix and heart disease. Lasix is ??more

Transportation 52

Transportation Patients Leads 52

European Pharmaceutical Review

JULY 26, 2023

Empagliflozin reduces risk of chronic kidney disease progression “CKD is closely linked to other cardio-renal-metabolic conditions such as type 2 diabetes and heart failure – thus an integrated approach is vital for optimised treatment of these interconnected conditions,” explained Dr Leonard Glass, F.A.C.E.,

Medicine 93

Medicine Pharma Patients Medical 93

European Pharmaceutical Review

MAY 16, 2023

1 Since the first therapy using stem cells was developed in 1957, only few stem cell-based therapies have entered the clinic 1 as advanced therapy medicinal products (ATMPs). in a 2023 paper published in the Journal of Clinical Microbiology. To facilitate this, regulation of cell therapies has transformed at pace in recent decades.

Manufacturing 86

Manufacturing Medicine Marketing Medical 86

Pharmaceutical Technology

FEBRUARY 7, 2023

The European Commission (EC) has granted approval for AstraZeneca ’s Forxiga (dapagliflozin), a first-in-class, oral, once-daily SGLT2 inhibitor, to treat symptomatic chronic heart failure (HF). The post EC approves AstraZeneca’s heart failure therapy Forxiga appeared first on Pharmaceutical Technology.

Patients 59

Patients Medicine Pharmaceutical 59

Pharmacy Times

JUNE 5, 2023

Treatment with Injectafer significantly improved exercise capacity compared to placebo in a randomized clinical trial in adult patients with heart failure.

FDA 52

FDA Patients 52

European Pharmaceutical Review

JUNE 21, 2023

The clinical trial was conducted among 5,522 patients with chronic coronary disease. For appropriate patients already taking a statin, adding the anti-inflammatory drug colchicine at a dose of 0.5mg daily has been proven to significantly lower risks of recurrent heart attack and stroke,” Dr Ridker added.

Food and Drug Administration 121

Food and Drug Administration Medicine FDA Food 121

Legacy MEDSearch

JULY 13, 2022

Ancora Heart , Inc., a company developing a novel device-based therapy to address heart failure, announced that the U.S. 1 “Early data on the AccuCinch System are promising, providing hope that this novel transcatheter approach may address the therapeutic gap for heart failure patients in the future.”.

Food and Drug Administration 52

Food and Drug Administration FDA Medical Recruitment 52

Pharmacy Times

OCTOBER 1, 2022

Empagliflozin has been found to lower the risk of death due to cardiovascular events and the number of first and recurrent heart failure hospitalizations.

Patients 48

Patients 48

Medgadget

JUNE 6, 2023

The deep tissue functionality and twelve hour battery life mean that the wearable is suitable to monitor a variety of useful physiological parameters, including cardiac output, blood pressure, and heart rate. Abnormal values of blood pressure and cardiac output, at rest or during exercise, are hallmarks of heart failure.

Training 126

Training Patients 126

Pharmacy Times

JUNE 2, 2023

Management of heart failure focuses on avoiding reversible precipitants and optimizing guideline-directed therapy to lower mortality and hospitalizations.

Patients 26

Patients Management 26

Legacy MEDSearch

APRIL 13, 2023

a privately held medical device company developing minimally invasive therapies to directly treat the dilated left ventricle and reverse the left ventricular remodeling process in patients with congestive heart failure, today announced the completion of $48.5 BioVentrix, Inc., million Series A round financing.

Food and Drug Administration 52

Food and Drug Administration Recruitment Medical Management 52

European Pharmaceutical Review

NOVEMBER 11, 2022

The American Heart Association (AHA)’s Scientific Sessions 2022 is a global exchange of the latest advancements in research and clinical practice of cardiovascular science. AHF is a major contributor to morbidity and mortality for heart failure patients. Researchers, presented at the American Heart Association conference.

Safety 103

Safety Medical Patients Transportation 103

Pharmacy Times

JANUARY 18, 2023

Study results shows that the use of a point-of-care tool and timely after care were essential to lowering the risk of hospitalization from cardiovascular disease within 30 days after acute HF.

Leads 26

Leads 26

Pharmaceutical Technology

SEPTEMBER 21, 2022

It leverages gene transfer technology to target the monogenic cause of BAG3-linked dilated cardiomyopathy (DCM), a severe kind of heart failure. . The Renovacor takeover is expected to further bolster the expertise of Rocket in AAV-based cardiac gene therapy, as well as support its near-term clinical assets to treat heart ailments. .

Pharmaceutical 59

Pharmaceutical Patients Medical 59

Legacy MEDSearch

AUGUST 25, 2022

Major adverse cardiac events and heart failure endpoints will be captured acutely and for up to 3 years. It is anticipated that a future patient-level pooled meta-analysis of the two studies will demonstrate a hard clinical endpoint improvement in heart failure hospitalization. said Olivier Delporte, CEO.

Medical 52

Medical FDA Recruitment Pharmacology 52

pharmaphorum

OCTOBER 10, 2022

Merck has multibillion-collar sales expectations for sotatercept, which will be at the heart of a renewed push into cardiovascular disease therapies. Merck has multibillion-collar sales expectations for sotatercept, which will be at the heart of a renewed push into cardiovascular disease therapies.

Sales 52

Sales FDA Pharma Competition 52

Legacy MEDSearch

JULY 19, 2022

Caption Health , the leader in using AI and services to improve heart ultrasound access, announced that it has received a CE Mark for its Caption AI technology platform. Medical devices and software require the CE Mark for clinical applications in several key regions including the UK and EU. million lives each year.

Recruitment 52

Recruitment Medical Leads Patients 52

Pharmaceutical Technology

JUNE 6, 2023

MRNA-0184 is an oligonucleotide commercialized by Moderna, with a leading Phase I program in Congestive Heart Failure (Heart Failure). According to Globaldata, it is involved in 1 clinical trial, which is ongoing. MRNA-0184 Overview mRNA-0184 is under development for the treatment decompensated heart failure.

Sales 40

Sales Leads Patients 40